Ozmosi | Fosdevirine Drug Profile

Product Description

Mechanisms of Action: NNRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: HIV Infections|Acquired Immunodeficiency Syndrome|Communicable Diseases|Deficiency Diseases

Phase 1: Communicable Diseases|HIV Infections|Acquired Immunodeficiency Syndrome|Deficiency Diseases|Herpesviridae Infections

Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
RT-167	N/A	Not yet recruiting	Type 1 Diabetes	2022-02-28
2011-003303-38	P2	Completed	HIV Infections	2013-02-19	2022-03-13	Treatments
SONNET	P2	Terminated	Deficiency Diseases\|Communicable Diseases\|Acquired Immunodeficiency Syndrome\|HIV Infections	2011-07-19	2019-03-19	Treatments
2010-018532-40	P2	Completed	HIV Infections	2011-07-19	2022-03-13	Treatments
SIGNET	P2	Terminated	HIV Infections\|Acquired Immunodeficiency Syndrome	2011-07-04	2019-03-19	Treatments
2010-018487-16	P2	Terminated	HIV Infections	2011-05-01	2022-03-13	Treatments
NCT01283100	P1	Withdrawn	Acquired Immunodeficiency Syndrome\|HIV Infections	2011-03-01	2019-03-19	Treatments
NCT01195974	P1	Terminated	HIV Infections\|Acquired Immunodeficiency Syndrome\|Deficiency Diseases\|Communicable Diseases	2011-02-09	2019-03-19	Primary Completion Date\|Start Date
NCT01273103	P1	Withdrawn	HIV Infections\|Acquired Immunodeficiency Syndrome	2011-02-01	2019-03-19	Treatments
NCT01209117	P1	Completed	Herpesviridae Infections\|Acquired Immunodeficiency Syndrome\|Deficiency Diseases\|Communicable Diseases\|HIV Infections	2011-01-01	2019-03-19	Treatments
NCT01138072	P1	Completed	HIV Infections\|Acquired Immunodeficiency Syndrome	2010-08-01	2019-03-19	Treatments
NCT01101893	P1	Completed	Acquired Immunodeficiency Syndrome\|HIV Infections	2010-06-01	2019-03-19	Treatments
NCT01031472	P1	Completed	Acquired Immunodeficiency Syndrome\|Communicable Diseases\|HIV Infections\|Deficiency Diseases	2010-03-11	2020-03-11	Primary Completion Date\|Primary Endpoints\|Start Date\|Study Completion Date\|Treatments
NCT00945282	P2	Completed	HIV Infections\|Acquired Immunodeficiency Syndrome	2009-11-28	2019-03-18
NCT00920088	P1	Completed	Acquired Immunodeficiency Syndrome\|HIV Infections	2009-11-01	2024-06-26	Primary Endpoints\|Treatments

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Fosdevirine

Alternative Names: fosdevirine, gsk-2248761, gsk2248761, gsk 2248761 Clinical Status: Inactive Latest Update: 2020-03-09 Latest Update Note: Clinical Trial Update